European Federation of Pharmaceutical Industries and Associations

#AstraZeneca #Drug discovery #Europe #European Federation of Pharmaceutical Industries and Associations #FDA #Francis Crick Institute #Hypertension #Lung cancer #Mental health #Tropical disease #University of Dundee #Wellcome Trust

DDW Highlights: 26 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a report showed patients in Europe face barriers to medicine access. Elsewhere,… Read More

#Podcasts

Europe
#Europe #European Federation of Pharmaceutical Industries and Associations #FDA

Patients in Europe face barriers to medicine access 

Patients in Europe are waiting longer to access medicines than patients in the US, a new report warns.  The European Federation of Pharmaceutical Industries and Associations (EFPIA)’s report shows 49% of FDA-approved medicines are not available in Europe, up from 46% in 2019.  Data also indicates 17% of medicines are… Read More

#Editor's Choice #News #Regulatory

UK
#BioIndustry Association #European Federation of Pharmaceutical Industries and Associations #Rare disease #UK

UK lags behind on access to treatments for rare diseases

The UK lags comparable countries, including France and Germany, on the degree of availability of treatments for rare diseases, according to a new report. The report by the BIA and consultancy firm PwC has highlighted the progress that has been made in improving access to rare… Read More

#News

In vitro diagnostics
#Clinical trials #EFPIA #EU #European Federation of Pharmaceutical Industries and Associations #In vitro #Pharmaceuticals #Regulatory

New EU in vitro regulations delaying clinical trials

New EU legislation designed to improve public health is delaying clinical trials and blocking access to new treatments for cancer and rare diseases, says the European Federation of Pharmaceutical Industries and Associations (EFPIA). The number of clinical trials delayed is expected to run into the hundreds, affecting up to 42,200… Read More

#News #Regulatory

EU flag
#Advanced Therapy Medicinal Products (ATMPs) #Alliance for Regenerative Medicine #Cell and gene therapy #EFPIA #EU #European Commission #European Federation of Pharmaceutical Industries and Associations #Market reporting

Can Europe become a major player in cell and gene therapy?

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies.  A new report by Charles River Associates… Read More

#Exclusive Content #Market Reports